Molecular subtypes as a prognostic breast cancer factor in women users of the São Paulo public health system, Brazil

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorFundação Oncocentro de São Paulo-
Autor(es): dc.contributorCancer Epidemiology and Statistics Group - São Paulo (SP)-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorGrupo Oncoclínicas de São Paulo-
Autor(es): dc.contributorGraduate Program in Oncology - Barretos (SP)-
Autor(es): dc.creatorPeres, Stela Verzinhasse-
Autor(es): dc.creatorArantes, Paola Engelmann-
Autor(es): dc.creatorFagundes, Marcela de Araújo-
Autor(es): dc.creatorAb'Saber, Alexandre Muxfeldt-
Autor(es): dc.creatorGimenes, Daniel Luiz-
Autor(es): dc.creatorCurado, Maria Paula-
Autor(es): dc.creatorVieira, René Aloisio da Costa-
Data de aceite: dc.date.accessioned2025-08-21T17:37:58Z-
Data de disponibilização: dc.date.available2025-08-21T17:37:58Z-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2022-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1590/1980-549720230028-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/249093-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/249093-
Descrição: dc.descriptionOBJECTIVE: This study aimed to analyze the prognosis of women with breast cancer by molecular subtypes, sociodemographic variables, and clinical and treatment characteristics. METHODS: This hospital-based retrospective cohort study analyzed 1,654 women over 18 years of age diagnosed with invasive breast cancer from 2000 to 2018. Data were extracted from Brazil's Oncocenter Foundation of São Paulo. The variables analyzed were age, histology, molecular subtypes, clinical staging, treatment type, and diagnosis-to-treatment time. Cox regression analysis was applied to estimate death risk. RESULTS: Women with HER-2-positive (nonluminal) and triple-negative molecular subtypes were more than twice more likely to be at risk of death, with adjusted hazard ratio - HRadj=2.30 (95% confidence interval - 95%CI 1.34-3.94) and HRadj=2.51 (95%CI 1.61-3.92), respectively. A delayed treatment associated with an advanced clinical stage at diagnosis increased fourfold the risk of death (HRadj=4.20 (95%CI 2.36-7.49). CONCLUSION: In summary, besides that interaction between advanced clinical stage and longer time between diagnosis and treatment, HER-2-positive (nonluminal) and triple-negative phenotypes were associated with a worse prognosis. Therefore, actions to reduce barriers in diagnosis and treatment can provide better outcome, even in aggressive phenotypes.-
Descrição: dc.descriptionFundação Oncocentro de São Paulo Department of Information and Epidemiology - São Paulo (SP)-
Descrição: dc.descriptionA.C. Camargo Cancer Center Centro International de Pesquisa Cancer Epidemiology and Statistics Group - São Paulo (SP)-
Descrição: dc.descriptionFundação Oncocentro de São Paulo Department of Pathology - São Paulo (SP)-
Descrição: dc.descriptionUniversidade de São Paulo Clinical Hospital - São Paulo (SP)-
Descrição: dc.descriptionGrupo Oncoclínicas de São Paulo Department of Mastology - São Paulo (SP)-
Descrição: dc.descriptionUniversidade de São Paulo Faculty of Medicine of Botucatu Graduate Program in Obstetrics and Gynecology - Botucatu (SP)-
Descrição: dc.descriptionHospital do Câncer de Barretos Graduate Program in Oncology - Barretos (SP)-
Formato: dc.formate230028-
Idioma: dc.languageen-
Relação: dc.relationRevista brasileira de epidemiologia = Brazilian journal of epidemiology-
???dc.source???: dc.sourceScopus-
Título: dc.titleMolecular subtypes as a prognostic breast cancer factor in women users of the São Paulo public health system, Brazil-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.